Kenvue Inc.
Kenvue Announces FY 2025 Results and Announces Restructuring Initiative
Summary
Kenvue Inc. reported its financial results for the full fiscal year and fourth quarter of 2025, showing a net sales increase of 3.2% and 1.2% organic sales growth in Q4. However, for the full year, net sales decreased by 2.1% and organic sales declined by 2.2%. The company also announced a restructuring initiative expected to result in a net global workforce reduction of approximately 3.5% and pre-tax restructuring expenses of approximately $250 million in 2026. Diluted EPS for Q4 was $0.17, up from $0.15 in the prior year, and full-year diluted EPS was $0.76. Adjusted diluted EPS for Q4 was $0.27 and $1.08 for the full year. The company did not provide forward-looking guidance due to the pending transaction with Kimberly-Clark.
Profitelligence Alerts
Get alerts for KVUE
Be first to know when Kenvue Inc. files with the SEC.
Filing Categories
Advertisement
About Kenvue Inc.
Kenvue Inc. is a consumer healthcare and pharmaceutical company. It focuses on delivering a range of health-centric products, spanning hygiene, pain relief, and other wellness categories. With deep-rooted expertise in pharmaceuticals, Kenvue Inc. targets the health and wellness needs of individuals, providing both prescription and over-the-counter solutions. The company has established itself as a vital entity in the consumer health sector, significantly impacting community health standards and individual lives. Positioned in the pharmaceutical industry, Kenvue Inc. collaborates with healthcare providers to enhance its product reach and efficacy. Its broad portfolio includes well-known brands and formulations that are trusted globally by consumers seeking reliable health solutions. As a player in this sector, Kenvue Inc. contributes to the enhancement of public health, highlighting its prominence in both domestic and international markets.
Official SEC Documents
Advertisement